Video

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia (CLL).

There is a highly specific kinase receptor binding in newer BTK inhibitors, says Seymour. For example, acalabrutinib (Calquence) and zanubrutinib (Brukinsa) have less binding on EGFR, therefore, it is believed that these agents will cause less gastrointestinal adverse effects in patients with CLL. Additionally, there is not as much binding on targets that are important for platelet inhibition with these BTK inhibitors, which could result in less bleeding in this patient population, adds Seymour.

The BTK inhibitors that are currently under development are being designed to have more favorable toxicity profiles, concludes Seymour.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity